Table 1 Demographics and clinical symptoms and level of bone markers between sex at baseline
Variables | Total (N = 102) | Male (N = 51) | Female (N = 51) | Statistics | |
|---|---|---|---|---|---|
N (%) | N (%) | N (%) | χ2 | p | |
MDD | 75 (73.5%) | 33 (64.7%) | 42 (82.4%) | 4.080 | 0.043 |
Married | 50 (49.0%) | 18 (35.3%) | 32 (62.7%) | 7.689 | 0.006 |
Employed | 43 (42.0%) | 16 (31.4%) | 27 (52.9%) | 4.865 | 0.027 |
Current smoking | 18 (17.6%) | 15 (29.4%) | 3 (5.9%) | 9.724 | 0.002 |
Current drinking | 3 (2.9%) | 3 (5.9%) | 0 (0%) | 3.091 | 0.079 |
On antipsychotics | 55 (53.9%) | 29 (56.9%) | 26 (51%) | 0.355 | 0.551 |
On benzodiazepine | 46 (45.1%) | 21 (41.2%) | 10 (19.6%) | 5.607 | 0.018 |
On mood stabilizer | 31 (30.4%) | 21 (41.2%) | 25 (49%) | 0.634 | 0.426 |
|  | Mean ± SD | Mean ± SD | Mean ± SD | t | p |
|---|---|---|---|---|---|
Age (year) | 34.20 ± 11.74 | 33.45 ± 11.59 | 34.94 ± 11.96 | 0.639 | 0.524 |
Education (year) | 12.47 ± 3.03 | 12.27 ± 3.02 | 12.67 ± 3.05 | 0.652 | 0.516 |
BMI (kg/m2) | 22.53 ± 3.03 | 23.70 ± 3.73 | 21.35 ± 2.91 | 3.548 | 0.001 |
Duration of disease (months) | 102.87 ± 94.40 | 127.04 ± 102.23 | 78.71 ± 79.74 | 2.662 | 0.009 |
Dose of antidepressant (mg/day)a | 36.66 ± 21.95 | 36.82 ± 23.28 | 36.50 ± 20.86 | 0.072 | 0.943 |
MADRS score | 32.14 ± 7.32 | 31.82 ± 7.36 | 32.45 ± 7.35 | 0.096 | 0.923 |
DKK1 (pg/ml) | 6.20 ± 0.36 | 6.20 ± 0.33 | 6.21 ± 0.40 | 0.114 | 0.914 |
Leptin (pg/ml) | 8.64 ± 1.17 | 8.36 ± 1.29 | 8.92 ± 0.97 | 6.238 | < 0.001 |
OPG (pg/ml) | 6.07 ± 0.30 | 6.08 ± 0.28 | 6.05 ± 0.32 | 0.613 | 0.539 |
OC (pg/ml) | 9.91 ± 0.94 | 9.86 ± 0.97 | 9.97 ± 0.92 | 0.081 | 0.937 |
OPN (pg/ml) | 10.2 ± 1.05 | 10.11 ± 1.20 | 10.3 ± 0.87 | 1.103 | 0.272 |
SOST (pg/ml) | 8.01 ± 0.86 | 8.01 ± 0.77 | 8.01 ± 0.95 | 0.331 | 0.740 |
PTH (pg/ml) | 4.42 ± 0.45 | 4.46 ± 0.49 | 4.38 ± 0.40 | 0.535 | 0.593 |
FGF23(pg/ml) | 4.48 ± 0.43 | 4.57 ± 0.48 | 4.39 ± 0.37 | 1.069 | 0.290 |